>>

>>

抑制剂/激活剂

>>

凋亡与自噬

>>

Stattic

Stattic 是一种有效的 STAT3 抑制剂，可以抑制 STAT3 磷酸化 (磷酸化位点为 Y705 和 S727)。Stattic 抑制高亲和力磷酸肽与 STAT3 的 SH2 域结合。Stattic 可改善 Alport 综合征 (AS) 小鼠的肾功能不全。

货号：
TK0316
规格：

5mg

10mg

25mg
价格：
￥0.00

产品参数

CAS No.	19983-44-9
生物活性	Stattic is a potent STAT3 inhibitor and inhibits STAT3 phosphorylation (at Y705 and S727). Stattic inhibits the binding of a high affinity phosphopeptide for the SH2 domain of STAT3. Stattic ameliorates the renal dysfunction in Alport syndrome (AS) mice.
分子式	C8H5NO4S
分子量	211.19
运输条件	Room temperature in continental US; may vary elsewhere.
储存条件	Powder -20°C 3 years
溶解性数据	DMSO : 50 mg/mL (236.75 mM; Need ultrasonic)
体内研究	Stattic (10 mg/kg; i.p.; three times per week for 10 week) ameliorates the renal dysfunction in Alport syndrome (AS) mice.
体外研究	Stattic (20 μM; 24 hours) inhibits STAT3 phosphorylation (Y705) and selectively inhibits P-STAT3 as demonstrated by the lack of inhibition of P-ERK1/2 in ALDH and D44/CD24 subpopulations of Panc-1 and HPAC pancreatic cancer cell lines. Stattic (2.5, 5, 10 μM; for 4 h) significantly reduces the nuclear level of pSTAT3 and survivin in PC3M-1E8 cells at 10 μM. Stattic (2.5-10 μM; for 24 h) inhibits IL-6-induced STAT3 activation in a dose-dependent manner. Stattic (2.5, 5, 10 μM; for 48 h) suppresses both the growth and induces apoptosis prostate cancer cells (PC3M-1E8 cells) with 10 μM. Stattic does not induce significant cell apoptosis with 2.5 μM, 5 μM. Stattic (2.5, 5, 10 μM; for 48 h) shows significant S phase accumulation. Stattic can not lead to significant morphological changes or apoptosis and has little STAT3 phosphorylation in A2780 cells and HUVECs.
文献	•Cell Metab. 2019 Jan 8;29(1):141-155.e9. •Gut. 2020 Jan;69(1):122-132. •Sci Transl Med. 2021 Oct 6;13(614):eabg6428. •Mol Cancer. 2019 Mar 30;18(1):64. •Nat Commun. 2021 Jun 15;12(1):3651. •J Immunother Cancer. 2020 Mar;8(1):e000111. •J Immunother Cancer. 2019 Jul 12;7(1):178. •J Immunother Cancer. 2018 Dec 18;6(1):151. •Redox Biol. 10 August 2021, 102098. •J Exp Clin Cancer Res. 2021 Jan 4;40(1):4. •J Exp Clin Cancer Res. 2018 Dec 20;37(1):321. •J Exp Clin Cancer Res. 2018 Jul 3;37(1):133. •Oncogene. 2022 Jan 7. •Cell Mol Gastroenterol Hepatol. 2019;7(2):255-274. •Br J Pharmacol. 2019 Jun;176(11):1717-1727. •Cancer Lett. 2021 Jun 14;S0304-3835(21)00294-9. •Cell Death Dis. 2022 Jan 10;13(1):36. •Cell Death Dis. 2021 Sep 28;12(10):886. •Cell Death Dis. 2021 Oct 5;12(10):910. •Cell Death Dis. 2019 Oct 14;10(10):781. •Cell Death Dis. 2018 Jan 18;9(2):25. •Pharmacol Res. 2019 Sep;147:104307. •Br J Cancer. 2021 Mar 26. •Am J Transplant. 2020 Dec;20(12):3354-3366. •Int J Nanomedicine. 11 January 2022. •Front Oncol. 2021 Nov 22;11:762523. •Mol Cancer Res. 2021 Jun 25. •Mol Cancer Res. 2019 Jun;17(6):1378-1390. •Cancer Cell Int. 2022 Jan 15;22(1):24. •Nutrients. 2019 Apr 5;11(4):791. •Mech Ageing Dev. 2020 Oct;191:111347. •Phytomedicine. 2020 Apr;69:153194. •J Cell Mol Med. 2019 Apr;23(4):2970-2983. •Int Immunopharmacol. 2021 Apr 2;96:107587. •Int Immunopharmacol. 2020 Apr;81:106240. •Mol Carcinog. 2017 Nov;56(11):2434-2445. •J Mol Biol. 2020 Sep 1;12(9):723-737. •Front Physiol. 2021 Aug 18;12:724470. •Cell Signal. 2019 Mar;55:65-72. •J Cancer. 2021; 12(16):4819-4829. •J Cancer. 2020 Jan 20;11(7):1859-1868. •Cancer Manag Res. 2021 May 7;13:3685-3697. •Ann Transl Med. 2021 May;9(9):784. •Oncol Rep. 2019 Jun;41(6):3219-3232. •IUBMB Life. 2018 Jan;70(1):81-91. •Biochem Biophys Res Commun. 2019 Jul 23;515(2):394-400. •Biochim Biophys Acta Gene Regul Mech. 2019 Aug;1862(8):796-806. •Immunobiology. 15 December 2021, 152165. •J Drug Deliv Sci Technol. 2020 Jul. •Exp Ther Med. 2020 Sep;20(3):2148-2156. •Exp Ther Med. 2020 Feb;19(2):1297-1303. •Research Square Preprint. 2022 Jan. •Research Square Preprint. 2021 Nov. •Chem Rev. 9 November 2021, 100155. •Research Square Preprint. 2021 Aug. •Research Square Preprint. 2021 Jul. •Research Square Preprint. 2020 Dec. •Research Square Preprint. 2020 Sep.
纯度及产品资料	≥98%

推荐产品